Comparing two chemotherapy combinations before colon cancer surgery
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial compares two different chemotherapy combinations given before surgery for locally advanced colon cancer. One option adds an immunotherapy drug to the chemo. The goal is to see which approach works better at shrinking the tumor and improving outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have colon cancer (not rectal) that is at a high-risk stage, like T4 or N2, according to scans.
- The cancer has not spread to distant organs like the liver or lungs.
- You have not had previous systemic treatment (like chemo or immunotherapy) for your colon cancer.
- You are generally healthy enough for treatment, with no major heart problems or uncontrolled toxic effects from prior treatments.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding immunotherapy (a treatment that helps your immune system fight cancer) to standard chemotherapy before surgery works better than chemotherapy alone for people with locally advanced colorectal cancer.
This trial tests whether giving chemotherapy before surgery can improve outcomes for patients with colon cancer that has not spread to other parts of the body. The treatment aims to shrink the tumor and reduce the chance of the cancer coming back.
This study compares two different chemotherapy combinations given after surgery to prevent cancer from coming back in people with colorectal cancer who have minimal residual disease (MRD), meaning there are still tiny traces of cancer DNA in the blood. A more intense regimen may work better for this group, and the trial checks if it is safe and more effective.
This Phase 2 trial studies giving chemotherapy plus immune therapy before surgery for certain colon cancers that do not have mismatch repair defects (MSS/pMMR). The goal is to shrink and control the tumor and improve outcomes compared with standard approaches.
This Phase 2 trial tests whether a newer combination chemotherapy plus an immunotherapy medicine (cadonilimab/AK104) works better than standard chemotherapy before surgery for locally advanced colorectal cancer. The goal is to shrink the tumor and improve how well treatment works after surgery.
This trial compares two chemotherapy combinations given before surgery for low rectal cancer. One group gets a standard chemo pill (CAPOX), while the other gets a more intense combination of three chemo drugs plus an immunotherapy drug (PD-1 inhibitor) to see which approach works better at shrinking tumors.
Hear when a new Colon Cancer (Stage II &Amp;Amp; III) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.